Similarly, although SGLT2 inhibitors (SGLT2is) have demonstrated cardiovascular benefits in patients with CKD through various mechanisms—such as improving endothelial function and vasodilation, optimizing myocardial energy metabolism, preserving cardiac contractility, and exerting anti-inflammatory effects [28,32,33]—the low usage rate of SGLT2is in our cohort limited our ability to identify a statistically significant association. The gene discussed is SLC5A2; the disease is chronic kidney disease.